Results 101 to 110 of about 240,836 (199)

Andexanet alfa: hét antidotum voor factor Xa-remmers?: Wat is de waarde voor de Nederlandse praktijk? [PDF]

, 2019
Tot voor kort waren er geen specifieke geneesmiddelen beschikbaar die de werking van bepaalde directe orale antistollingsmiddelen – de zogenoemde factor Xa-remmers – kunnen antagoneren.
Huisman, M.V., Klok, F.A.
core  

SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS

Атеротромбоз, 2016
Safety profiles of the novel oral anticoagulants (NOAC) (rivaroxaban, apixaban, edoxaban,  dabigatran) are better than that of warfarin. However, the risk (including lifethreatening) of bleeding  is no less than 2.3–3.1% per year.
O. O. Shakhmatova
doaj   +1 more source

Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee

Transfusion, Volume 65, Issue 9, Page 1728-1737, September 2025.
Elizabeth P. Crowe, Jennifer Andrews, Stella T. Chou, Claudia S. Cohn, Mischa L. Covington, Ruchika Goel, Aaron S. Hess, Tina S. Ipe, Jessica Jacobson, Cyril Jacquot, Jenna Khan, Michael F. Murphy, Kerry O'Brien, Monica B. Pagano, Anil K. Panigrahi, Jacqueline N. Poston, Eric Salazar, Nabiha H. Saifee, Moritz Stolla, Nicole D. Zantek, Alyssa Ziman, Ryan A. Metcalf   +21 more
wiley   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Supplemental Material, Appendix_A - Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

, 2019
Supplemental Material, Appendix_A for Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center by Victoria M. Stevens, Toby Trujillo, Scott W.
Victoria M. Stevens (8194119), Paul M. Reynolds (1292766), Robert MacLaren (5102381), Scott W. Mueller (5216267), Tyree H. Kiser (5216270), Toby Trujillo (8194122)   +5 more
core   +1 more source

Impact of code stroke on door-to-andexanet administration time for factor Xa inhibitor-associated intracranial hemorrhage: a single-center retrospective study

Frontiers in Neurology
BackgroundAdministration of andexanet alfa has shown to achieve hemostatic efficacy in factor Xa inhibitor (FXai)-associated intracranial hemorrhage (ICrH). Code stroke (CS), implemented through the visual task management application Task Calc.
Koji Tanaka, Eri Imazu, Takuma Ishihara, Junpei Koge, Tetsuya Hashimoto, Kazuyasu Matsumura, Eiji Fujiwara, Kenichiro Suyama, Jun Muto, Motoharu Hayakawa, Ayuko Yasuda, Ichiro Nakahara, Hiroshi Koyama, Jun-ichi Kira, Jun-ichi Kira, Yuichi Hirose, Shoji Matsumoto   +16 more
doaj   +1 more source

Andexanet Alfa and its Clinical Application [PDF]

Heart International, 2020
Fauve A, Noordergraaf, Marco, Alings
openaire   +2 more sources

Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis

Neurocritical Care
Factor Xa inhibitors (FXaI) are increasingly used for anticoagulation therapy, yet their association with intracranial hemorrhage poses a significant challenge.
Khalid Sarhan, Rashad G. Mohamed, R. Elmahdi, Y. Mohsen, A. Elsayed, D. Zayed, M. A. Elkholi, N. Gabr, E. M. El-bialy, I. Serag   +9 more
semanticscholar   +1 more source

Andexanet Alfa versus Four-Factor Prothrombin Complex Concentrate for the Reversal of Factor Xa (FXa) Inhibitor-Associated Intracranial Hemorrhage: A Systematic Review of Retrospective Studies

Journal of Clinical Medicine
Background/Objectives: There are limited data on the risks and benefits of using Andexanet alfa (AA) compared with four-factor prothrombin complex concentrate (4F-PCC) for the reversal of factor Xa inhibitor-associated intracranial hemorrhage (ICH).
L. O. Ferreira, Ricardo Andres León Oldemburg, João Monteiro Leitão, R. A. Cerveira, Victoria Winkler Vasconcelos, G. E. da Costa, Roseny dos Reis Rodrigues, D. Lopes   +7 more
semanticscholar   +1 more source

Specific reversal agents for direct oral anticoagulants in neurosurgical emergencies – a systematic review

Research and Practice in Thrombosis and Haemostasis
Background: Direct oral anticoagulants (DOACs) are widely used but pose significant challenges in emergency neurosurgical settings. Idarucizumab and andexanet alfa are approved reversal agents, yet their effectiveness and safety in neurosurgical ...
Laura Zeller, Jonas Rohr, Giovanna Brandi, Christoph Globas, Alexander Kaserer, Matthias Greutmann, Tilman Schubert, Jan-Dirk Studt, Katharina Geiling, Luca Regli, Menno R. Germans   +10 more
doaj   +1 more source